MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務。

Dolutegravir sodium

CAS No. : 1051375-19-9

MCE 國際站：Dolutegravir sodium

產(chǎn)品活性：Dolutegravir sodium (S/GSK1349572 sodium) 是一種高效、口服的 HIV 整合酶鏈轉(zhuǎn)移抑制劑，在 HIV-1 整合酶催化的鏈轉(zhuǎn)移中的 IC₅₀ 值為 2.7 nM，Dolutegravir sodium (S/GSK1349572 sodium) 抑制 HIV-1 病毒在外周血單個核細胞中的復制，IC₅₀ 為 0.51 nM。Dolutegravir sodium (S/GSK1349572 sodium) 對 Y143R，N155H 和 G140S/Q148H 突變體也保持高效 (EC₅₀=3.6-5.8 nM)。

研究領域：Metabolic Enzyme/Protease  |  Anti-infection

作用靶點：HIV Integrase  |  HIV

In Vitro: The EC₅₀ of Dolutegravir (S/GSK1349572) against HIV-1 is 0.51 nM in PBMCs, 0.71 nM in MT-4 cells, and 2.2 nM in the PHIV assay, which uses a pseudotyped self-inactivating virus. The 50% cytotoxic concentrations (CC₅₀) for Dolutegravir in proliferating IM-9, U-937, MT-4, and Molt-4 cells are 4.8, 7.0, 14, and 15 μM, respectively. In unstimulated and stimulated PBMCs, the CC₅₀ are 189 μM and 52 μM, respectively. Based on the EC₅₀ of Dolutegravir against HIV-1 in PBMCs (i.e., 0.51 nM), this translates to a cell-based therapeutic index of at least 9,400.

In Vivo: Following a single intravenous (IV) administration of Dolutegravir, the plasma clearance is low in rats (0.23?mL/min/kg) and monkeys (2.12?mL/min/kg). The half-lives in the rat and monkey are similar, approximately 6?h, and the steady-state volume of distribution (V_SS) is low. Following oral administration, Dolutegravir is rapidly absorbed with a high oral bioavailability when administered as a solution to fasted male rats and a single monkey (75.6 and 87.0%, respectively). Dolutegravir exposure (C_max and AUC) increased with increasing dose following oral administration of a suspension to non-fasted rats up to 250?mg/kg and non-fasted monkeys up to 50?mg/kg, although the increase is less than proportional.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  EMA-Approved Drug Library  |  Cytokine Inhibitors Library  |  Peldesine dihydrochloride  |  Abacavir sulfate  |  HIV-IN-6  |  Epicoccone B  |  Ditiocarb  |  Nevirapine  |  DAPTA  |  Aloperine  |  Elipovimab  |  HIV-1 inhibitor-52  |  PMEDAP  |  Integracin B  |  FNC-TP  |  DDX3-IN-1  |  Sennoside A  |  CK-666  |  HIV-1 inhibitor-44  |  Flavopiridol  |  Claficapavir  |  Atazanavir  |  1-Deoxymannojirimycin hydrochloride  |  TC14012  |  ddUTP  |  (Z)-9-Propenyladenine  |  Apabetalone  |  CCR5 antagonist 2  |  2F5 epitope  |  HIV-1 inhibitor-23  |  Apelin-36(rat, mouse)  |  MIV-150

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物  |  寡核苷酸  |  抗體  |  點擊化學

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry